MediciNova
US-based MediciNova develops small molecule therapeutics for various diseases, focusing on the US market.
Founded
2000US-based MediciNova develops small molecule therapeutics for various diseases, focusing on the US market.
Founded in La Jolla, United States, MediciNova, Inc. is a biopharmaceutical company dedicated to acquiring and developing small molecule therapeutics aimed at treating a range of diseases, including asthma, COPD, progressive multiple sclerosis, neuropathic pain, methamphetamine addiction, interstitial cystitis, and solid tumor cancers. The company's core mission is to provide innovative medical solutions that address unmet medical needs, primarily focusing on the healthcare market in the United States.
MediciNova has garnered attention for its impactful research and development efforts. Notable affiliated individuals include experts in the fields of neurology and pulmonology. The company has attracted significant investment from both private and institutional investors, enabling it to advance its clinical trials and expand its therapeutic pipeline. Key achievements include progressing several drug candidates through various stages of clinical trials, which has the potential to significantly impact patient care and treatment outcomes in its targeted disease areas.
Companies similar to MediciNova include Medinox, Link Medicine, Traws Pharma and Theravance Biopharma.
MediciNova was founded in 2000.
MediciNova's headquarters is located in Los Angeles, CA, US.
MediciNova's most recent funding round was for $20M (USD) in January 2021.
As of Jan 12, 2021, MediciNova has disclosed funding of $136M (USD). Undisclosed round amounts are excluded.
MediciNova has 13 employees as of Feb 6, 2024.
Theravance Biopharma
theravance.com
